EGFR and non-small cell lung carcinoma: This combination resulted in a trend towards improved RR (71% vs. 42%), PFS (10 vs. 7 months; HR 0.61–95% CI 0.36–1.03), and OS (26 vs. 20 months; HR 0.91–95% CI 0.53–1.59) compared to chemotherapy plus bevacizumab alone among patients with EGFR-mutant NSCLC; however, the differences were not statistically significant [105,106].